Viking Therapeutics Reports Third-Quarter 2026 Results and Pipeline Update
Viking said its Phase 3 trials of subcutaneous VK2735 in obesity continue to advance, initiated Phase 3 trials of oral VK2735, and reported positive top-line results from a VK2735 maintenance-dosing study, with Part 2 initiated. A Phase 1 single-ascending-dose study of VK3019 is nearing completion.